Last Updated: June 22, 2026

CLORAZEPATE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Clorazepate, and what generic alternatives are available?

Clorazepate is a drug marketed by Able, Am Therap, Dava Pharms Inc, Gd Searle Llc, Natco Pharma Usa, Purepac Pharm, Quantum Pharmics, Rising, Usl Pharma, Warner Chilcott, Watson Labs, Aurobindo Pharma, Aurolife Pharma Llc, Corepharma, Lederle, Novitium Pharma, Sun Pharm Inds Ltd, and Taro. and is included in fifty-eight NDAs.

The generic ingredient in CLORAZEPATE is clorazepate dipotassium. There are eight drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the clorazepate dipotassium profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Clorazepate

A generic version of CLORAZEPATE was approved as clorazepate dipotassium by AUROBINDO PHARMA on July 17th, 1987.

  Start Trial

AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for CLORAZEPATE?
  • What are the global sales for CLORAZEPATE?
  • What is Average Wholesale Price for CLORAZEPATE?
Summary for CLORAZEPATE
US Patents:0
Applicants:18
NDAs:58
Drug Prices: Drug price information for CLORAZEPATE
DailyMed Link:CLORAZEPATE at DailyMed

US Patents and Regulatory Information for CLORAZEPATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Watson Labs CLORAZEPATE DIPOTASSIUM clorazepate dipotassium TABLET;ORAL 071854-001 Feb 9, 1988 DISCN No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Aurobindo Pharma CLORAZEPATE DIPOTASSIUM clorazepate dipotassium TABLET;ORAL 071858-003 Jul 17, 1987 AB RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Watson Labs CLORAZEPATE DIPOTASSIUM clorazepate dipotassium CAPSULE;ORAL 071879-001 Mar 15, 1988 DISCN No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Lederle CLORAZEPATE DIPOTASSIUM clorazepate dipotassium TABLET;ORAL 072013-001 Dec 15, 1987 DISCN No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Quantum Pharmics CLORAZEPATE DIPOTASSIUM clorazepate dipotassium TABLET;ORAL 071702-001 Oct 26, 1987 DISCN No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Aurolife Pharma Llc CLORAZEPATE DIPOTASSIUM clorazepate dipotassium TABLET;ORAL 072514-001 May 11, 1990 DISCN No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Lederle CLORAZEPATE DIPOTASSIUM clorazepate dipotassium TABLET;ORAL 072014-001 Dec 15, 1987 DISCN No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration
DrugChatter Q&A for CLORAZEPATE

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.